Mesenchymal Stem Cell Culture Medium Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional culture media for mesenchymal stem cells have limitations in promoting high growth rates and maintaining undifferentiated states, leading to challenges in mass-producing these cells for therapeutic applications.
Innovation Solution
An advanced basic culture medium (ABM-M) is developed by combining DMEM high glucose, RPMI-1640, and Ham's F-12 at a 1:1:1 ratio, with specific components like amino acids, inorganic salts, and vitamins at optimized concentrations, and supplemented with fetal bovine serum and L-glutamine, to enhance cell proliferation and differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional culture media (α-MEM or DMEM with 10-20% fetal bovine serum) are used for mesenchymal stem cell culture, then the cells can be maintained with basic nutritional support, but the growth rate remains low and the cells are difficult to maintain in an undifferentiated state for long periods
Solution Approach 1:
The patent modifies the culture medium composition by changing parameters such as glucose concentration (using high glucose DMEM), amino acid composition, and supplement additions. Specifically, it uses DMEM high glucose as base medium and optimizes the concentration of nutrients to enhance cell proliferation while maintaining undifferentiated state, directly addressing the contradiction between growth rate and maintenance of stem cell characteristics
Solution Approach 2:
The patent creates a composite culture medium by combining multiple components: DMEM high glucose base medium, supplemented with specific amino acids (L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-hydroxy-L-proline, L-proline), inorganic salts, vitamins, and growth factors. This composite formulation synergistically enhances both proliferation and undifferentiated state maintenance
2Quantity of substance
If mesenchymal stem cells are cultured in conventional media for extended periods, then more cells can be obtained, but the cells undergo differentiation and lose their therapeutic potential
Solution Approach 1:
The patent adjusts medium parameters including glucose concentration, amino acid profiles, and supplement levels to create an environment that supports long-term culture without differentiation. The high glucose DMEM base with optimized amino acid composition provides sustained energy and building blocks for cell division while maintaining karyotype stability
Solution Approach 2:
The patent establishes continuous cell proliferation through optimized medium formulation that maintains undifferentiated state throughout extended culture periods. The combination of nutrients, growth factors, and controlled conditions enables uninterrupted cell division while preserving stem cell characteristics, allowing large-scale production without loss of therapeutic potential
3Ease of manufacture
If the culture medium is simplified to reduce cost, then manufacturing becomes easier, but the growth rate and cell maintenance capability deteriorate
Solution Approach 1:
The patent uses DMEM high glucose as a universal base medium that can be readily prepared from standard reagents, making the formulation accessible and easy to manufacture. By building upon this common platform and adding specific supplements (amino acids, inorganic salts, vitamins), the patent achieves enhanced performance without requiring complex or rare components, thus maintaining ease of manufacture while improving productivity
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
Disclosed is a basic culture medium for mesenchymal stem cells, and a cell therapeutic agent cultured and differentiated using same. The basic culture medium reduces the time taken from collection to mass culturing by increasing the proliferation rate of undifferentiated mesenchymal stem cells derived from an adult tissue such as human marrow and adipose tissue, and also is capable of various differentiations into treating agents for bone-forming cells, for cartilage cells, or for fat cells.